Exploring the effect of the supplement AB070597 in humans with declining kidney function

Exploratory-data and statistical analyses of AB070597, an amino acid and peptide complex, on blood-serum creatinine concentration and estimated glomerular filtration rate: a non-randomized pilot trial of five humans with declining renal-function

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN44802329

Enrollment

Registered

2020-08-25

Start date

2016-11-30

Completion date

Unknown

Last updated

2021-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Declining renal function in chronic kidney disease Urological and Genital Diseases Chronic kidney disease, chronic renal failure

Interventions

The intervention is oral administration of a daily dose of a specific amino acid/peptide complex. All participants are asked to follow the dosing schedule of six 1000 mg capsules, taken twice daily. E

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: 1. Aged 63 to 80 years 2. White 3. Male 4. Under concurrent medical care in the United States 5. Chronic kidney disease (CKD) or an estimated glomerular filtration rate (eGFR) decline rate of =4 ml/min/1.73 m² over the previous 24 months 6. History of increasing blood-serum creatinine from CKD or as a consequence of aging

Exclusion criteria

Exclusion criteria: 1. Concurrent or suspected comorbidities unrelated to CKD 2. Diabetic

Design outcomes

Primary

Measure	Time frame
1. Estimated glomerular filtration rate (eGFR) calculated from participant age and blood-serum creatinine concentration at baseline, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12 months 2. Individual eGFR median-rate-of-change per unit time compared to eGFR medium-rate-of-change per unit time of 2870 chronic kidney disease participants in a study by Tsai CW, et al. (2017) using non-parametric one-sample Wilcoxon signed-rank test	—

Measure

Time frame

1. Estimated glomerular filtration rate (eGFR) calculated from participant age and blood-serum creatinine concentration at baseline, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12 months 2. Individual eGFR median-rate-of-change per unit time compared to eGFR medium-rate-of-change per unit time of 2870 chronic kidney disease participants in a study by Tsai CW, et al. (2017) using non-parametric one-sample Wilcoxon signed-rank test

—

Secondary

Measure	Time frame
1. Estimated glomerular filtration rate measured by blood-serum creatinine and age at baseline, 12, 34, and 36 weeks	—

Countries

United States of America

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026